UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 276

Sortiert nach

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Blood, 2019-08, Vol.134 (8), p.668-677

2019

Volltextzugriff (PDF)

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours

British journal of cancer, 2010-09, Vol.103 (7), p.987-992

2010

Volltextzugriff (PDF)

Genetic markers in clinically well defined patients with ulcerative colitis (UC)

Clinical and experimental immunology, 1999-02, Vol.115 (2), p.294-300

1999

Volltextzugriff (PDF)

Prognostic value of bcl-2 expression in invasive breast cancer

British journal of cancer, 1995-08, Vol.72 (2), p.354-360

1995

Volltextzugriff (PDF)

1234 POSTER A First in Man Phase 1 Study of JNJ-26481585, a Novel Oral Histone Deacetylase Inhibitor (HDACi) in Advanced Cancer Patients -Evidence of Target Modulation, Antitumour Activity and Additional Safety Data in an Expanded Patient Cohort

European journal of cancer (1990), 2011, Vol.47, p.S154-S155

2011

Volltextzugriff (PDF)

Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study

BLOOD, 2021-11, Vol.138 (Supplement 1), p.1667-1667

2021

Volltextzugriff (PDF)

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Leukemia & lymphoma, 2023-01, Vol.64 (2), p.468-472

2023

Volltextzugriff (PDF)

Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study

JOURNAL OF CLINICAL ONCOLOGY, 2020, Vol.38 (15_suppl), p.8537-8537

2020

Volltextzugriff (PDF)

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

BLOOD, 2018-11, Vol.132 (Supplement 1), p.1995-1995

2018

Volltextzugriff (PDF)

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

BLOOD, 2018-11, Vol.132 (Supplement 1), p.2006-2006

2018

Volltextzugriff (PDF)

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

BLOOD, 2017-12, Vol.130 (Suppl_1), p.838-838

2017

Volltextzugriff (PDF)

Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO)

JOURNAL OF CLINICAL ONCOLOGY, 2018, Vol.36 (15_suppl), p.8013-8013

2018

Volltextzugriff (PDF)

Fetal fibronectin detection for prediction of preterm birth in low risk women

BJOG : an international journal of obstetrics and gynaecology, 1995-03, Vol.102 (3), p.207-212

1995

Volltextzugriff (PDF)

6MO Subcutaneous amivantamab administered every 4 weeks (Q4W) in patients with advanced solid malignancies: The phase Ib PALOMA study

ESMO open, 2024-03, Vol.9, p.102585, Article 102585

2024

Volltextzugriff (PDF)

Evidence for genetic heterogeneity in inflammatory bowel disease (IBD); HLA genes in the predisposition to suffer from ulcerative colitis (UC) and Crohn's disease (CD)

Clinical and experimental immunology, 1997-07, Vol.109 (1), p.175-179

1997

Volltextzugriff (PDF)

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

BLOOD, 2016-12, Vol.128 (22), p.1149-1149

2016

Volltextzugriff (PDF)

350 POSTER Measurement of mechanistic markers of histone deacetylase (HDAC) inhibition in samples from clinical trials

European journal of cancer supplements, 2008, Vol.6 (12), p.111-111

2008

Volltextzugriff (PDF)

Re: Tumor Angiogenesis as a Prognostic Assay for Invasive Ductal Breast Carcinoma

JNCI : Journal of the National Cancer Institute, 1995-12, Vol.87 (23), p.1797-1798

1995

Volltextzugriff (PDF)

An open-label, dose-escalation phase lb study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO)

JOURNAL OF CLINICAL ONCOLOGY, 2016, Vol.34 (15)

2016

Volltextzugriff (PDF)

A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3024-3024

2011

Volltextzugriff (PDF)

Preliminary results of an open-label phase I pharmacokinetic/pharmacodynamic study of JNJ26481585: Early evidence of antitumor activity

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e13504-e13504

2009

Volltextzugriff (PDF)

Essai multicentrique de phase 2 évaluant le quisinostat oral (inhibiteur d’histone déacétylase, iHDAC) chez des patients atteints de lymphome T cutané (LTC) au stade IB-IVA déjà traité

Annales de dermatologie et de vénéréologie, 2013-12, Vol.140 (12), p.S378-S379

2013

Volltextzugriff (PDF)

Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast

Journal of clinical pathology, 1995-02, Vol.48 (2), p.147-150

1995

Volltextzugriff (PDF)

Placebo-controlled trial of high-dose Mesterolone treatment of idiopathic male infertility

Fertility and sterility, 1991-03, Vol.55 (3), p.603-607

1991

Volltextzugriff (PDF)

Fetal Fibronectin Detection for Prediction of Preterm Birth in Low Risk Women

Obstetrical & gynecological survey, 1995-09, Vol.50 (9), p.639-640

1995

Volltextzugriff (PDF)

1 – 25 von 276

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(232)
Mit Volltextzugriff
(239)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(143)
Life Sciences & Biomedicine
(104)
Humans
(89)
Male
(57)
Female
(52)
Biological And Medical Sciences
(50)
Medical Sciences
(43)
Middle Aged
(33)
Animals
(31)
Adult
(30)
Physical Sciences
(30)
Physics
(30)
Aged
(28)
Medicin Och Hälsovetenskap
(17)
Rats
(15)
Genetics & Heredity
(13)
Cardiac & Cardiovascular Systems
(12)
Cardiovascular System & Cardiology
(12)
Fundamental And Applied Biological Sciences. Psychology
(12)
Life Sciences
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours

Genetic markers in clinically well defined patients with ulcerative colitis (UC)

Prognostic value of bcl-2 expression in invasive breast cancer

1234 POSTER A First in Man Phase 1 Study of JNJ-26481585, a Novel Oral Histone Deacetylase Inhibitor (HDACi) in Advanced Cancer Patients -Evidence of Target Modulation, Antitumour Activity and Additional Safety Data in an Expanded Patient Cohort

Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO)

Fetal fibronectin detection for prediction of preterm birth in low risk women

6MO Subcutaneous amivantamab administered every 4 weeks (Q4W) in patients with advanced solid malignancies: The phase Ib PALOMA study

Evidence for genetic heterogeneity in inflammatory bowel disease (IBD); HLA genes in the predisposition to suffer from ulcerative colitis (UC) and Crohn's disease (CD)

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

350 POSTER Measurement of mechanistic markers of histone deacetylase (HDAC) inhibition in samples from clinical trials

Re: Tumor Angiogenesis as a Prognostic Assay for Invasive Ductal Breast Carcinoma

An open-label, dose-escalation phase lb study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO)

A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity

Preliminary results of an open-label phase I pharmacokinetic/pharmacodynamic study of JNJ26481585: Early evidence of antitumor activity

Essai multicentrique de phase 2 évaluant le quisinostat oral (inhibiteur d’histone déacétylase, iHDAC) chez des patients atteints de lymphome T cutané (LTC) au stade IB-IVA déjà traité

Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast

Placebo-controlled trial of high-dose Mesterolone treatment of idiopathic male infertility

Fetal Fibronectin Detection for Prediction of Preterm Birth in Low Risk Women

Suchergebnisse filtern